bb 2121

Drug Profile

bb 2121

Alternative Names: Anti-BCMA CART cells - bluebird bio/Celgene; bb2121

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator bluebird bio
  • Developer bluebird bio; Celgene Corporation
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Multiple myeloma

Most Recent Events

  • 21 Feb 2018 bluebird bio completes enrolment in the CRB-401 phase I trial for Multiple myeloma (Second-line therapy or greater) in USA (NCT02658929)
  • 21 Feb 2018 bluebird bio announces intention to submit MAA to European Medicines Agency for Multiple myeloma (Second-line therapy or greater) in 2019
  • 08 Jan 2018 Celgene in collaboration with bluebird bio plans a phase III trial for Multiple myeloma (second-line therapy or greater) in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top